Trial Profile

A retrospective study assessing the efficacy of Apremilast in lupus rashes refractory to conventional treatment

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apremilast (Primary)
Indications Discoid lupus erythematosus; Systemic lupus erythematosus
Focus Therapeutic Use

Most Recent Events

15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
24 Oct 2018 Results assessing apremilast for the treatment of refractory skin lupus lesions, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
14 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com